Edge Therapeutics (EDGE) Stock Rating Upgraded by BidaskClub
Edge Therapeutics (NASDAQ:EDGE) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Saturday.
EDGE has been the subject of a number of other research reports. Zacks Investment Research raised Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Monday, November 6th. Credit Suisse Group reiterated an “outperform” rating and issued a $17.00 target price on shares of Edge Therapeutics in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $20.00.
Edge Therapeutics (EDGE) opened at $12.40 on Friday. The company has a market capitalization of $382.65 and a PE ratio of -7.95. Edge Therapeutics has a 52 week low of $7.30 and a 52 week high of $12.70. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.34 and a quick ratio of 8.34.
In other Edge Therapeutics news, CEO Brian A. Leuthner sold 2,500 shares of Edge Therapeutics stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $10.92, for a total value of $27,300.00. Following the transaction, the chief executive officer now owns 102,736 shares in the company, valued at $1,121,877.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brian A. Leuthner sold 5,000 shares of Edge Therapeutics stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $10.11, for a total value of $50,550.00. Following the completion of the transaction, the insider now owns 87,736 shares in the company, valued at approximately $887,010.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,361 shares of company stock worth $292,035. Company insiders own 36.19% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in EDGE. Voya Investment Management LLC bought a new position in Edge Therapeutics in the second quarter valued at about $106,000. Russell Investments Group Ltd. grew its position in Edge Therapeutics by 16.9% in the second quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,733 shares during the last quarter. Trexquant Investment LP bought a new position in Edge Therapeutics in the third quarter valued at about $130,000. Wells Fargo & Company MN grew its position in Edge Therapeutics by 44.4% in the third quarter. Wells Fargo & Company MN now owns 17,249 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 5,307 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Edge Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 3,764 shares during the last quarter. Hedge funds and other institutional investors own 50.26% of the company’s stock.
About Edge Therapeutics
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.